Home › Germ Cell and Embryonal Cancer
Germ Cell and Embryonal Cancer clinical trials recruiting in the U.S.
21 studies for Germ Cell and Embryonal Cancer are recruiting participants at sites across the United States.
Cities with the most studies
- Houston, TX6 studies
- New York City, NY5 studies
- Columbus, OH5 studies
- St. Louis, MO4 studies
- Indianapolis, IN4 studies
- Chicago, IL4 studies
- Memphis, TN3 studies
- Clifton, NJ3 studies
- Minneapolis, MN3 studies
- Mountain View, CA3 studies
- San Francisco, CA3 studies
- Dallas, TX3 studies
- Boston, MA3 studies
- Winston-Salem, NC3 studies
- San Bernardino, CA3 studies
- San Antonio, TX3 studies
- Greenburgh, NY3 studies
By state
- California7 studies
- Florida3 studies
- Georgia3 studies
- Illinois4 studies
- Indiana4 studies
- Massachusetts3 studies
- Michigan3 studies
- Minnesota3 studies
- Missouri4 studies
- New Jersey4 studies
- New York6 studies
- North Carolina3 studies
- Ohio5 studies
- Pennsylvania3 studies
- Tennessee4 studies
- Texas7 studies
Recently updated studies
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
RecruitingPhase 1
36 Months – 22 Years · All sexes · Updated Sep 4, 2026 · NCT03911388Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
RecruitingPhase 3
Ages 11 to 50 · All sexes · Updated Sep 1, 2026 · NCT02582697Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
RecruitingPhase 1
Ages 15 and older · All sexes · Updated Aug 25, 2026 · NCT06276491Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
RecruitingPhase 3
All ages · All sexes · Updated Aug 25, 2026 · NCT03067181Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
RecruitingPhase 1/2
Ages 12 to 80 · All sexes · Updated Aug 7, 2026 · NCT05092451C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)
RecruitingPhase 1
12 Months – 25 Years · All sexes · Updated Aug 3, 2026 · NCT04099797Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT07628634A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy
RecruitingPhase 2
Ages 18 to 70 · All sexes · Updated Jul 24, 2026 · NCT06866964Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
RecruitingPhase 1/2
Ages 4 to 39 · All sexes · Updated Jul 20, 2026 · NCT05278208Patient Reported Experiences With Sparing External Oblique Fascia Vs Standard Inguinal Orchiectomy
Recruiting
Ages 18 and older · Men · Updated Jul 10, 2026 · NCT06828185A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated May 27, 2026 · NCT03093116B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RecruitingPhase 1
Up to age 21 · All sexes · Updated May 19, 2026 · NCT04897321Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 8, 2026 · NCT04804007A Study of ZW251 in Participants With Advanced Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated May 7, 2026 · NCT07164313A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.
RecruitingEarly phase 1
Ages 3 to 21 · All sexes · Updated Apr 29, 2026 · NCT07017816Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
RecruitingPhase 1
Ages 1 to 30 · All sexes · Updated Apr 15, 2026 · NCT04308330Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
RecruitingPhase 1
Ages 1 to 26 · All sexes · Updated Apr 13, 2026 · NCT04185038The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Apr 13, 2026 · NCT01890486Germ Cell Tumor and Testicular Tumor DNA Registry
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Feb 4, 2026 · NCT02099734Maintenance Zanzalintinib With Etoposide After HDCT in GCT
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 21, 2025 · NCT06937866Molecular Epidemiology of Pediatric Germ Cell Tumors
RecruitingObservational study
All ages · All sexes · Updated Oct 24, 2025 · NCT05564026From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.